Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2024 | Story Precious Shamase | Photo Suplied
Prof Jesse Lutabingwa
Prof Jesse Lutabingwa, the visiting scholar who will be facilitating grant-writing workshops to support third-stream aspirations.

The University of the Free State (UFS) welcomes Prof Jesse Lutabingwa, a visiting Fellow from the Appalachian State University (AppState) in the United States. Prof Lutabingwa arrives under the prestigious Carnegie African Diaspora Fellowship Programme (CADFP), bringing a wealth of experience to support the university's ‘third-income aspirations.’

Prof Lutabingwa’s long-standing connection with the UFS began in 2009 when he played a pivotal role in establishing a collaborative partnership between the two institutions. At the time, he was serving as Associate Vice-Chancellor for International Education and Development at AppState. Now, he returns not as an administrator, but as a faculty member eager to share his expertise and deepen this valuable connection.

"I have always wanted to participate in CADFP to give back to the African continent," Prof Lutabingwa explains. "This fellowship allows me to engage with the UFS community on different issues and contribute to the professional and individual growth of faculty, staff, and students, ultimately serving our communities better."

Empowering through grant writing

A key aspect of Prof Lutabingwa’s fellowship is a series of grant-writing workshops designed to empower UFS faculty, researchers, and postgraduate students, particularly on the Qwaqwa Campus.

"Many find the idea of proposing research grants daunting," Prof Lutabingwa says. "My goal is to elucidate the process. With more than 33 years of experience and more than 65% success rate, I am here to share the knowledge I have gained as a grant writer and reviewer."

These workshops will equip participants with the skills and strategies needed to craft compelling proposals, significantly increasing their chances of securing funding. Access to grants is crucial, Prof Lutabingwa emphasises, as it allows researchers to pursue innovative work that benefits society while offering valuable training opportunities for students.

Collaboration for research impact

Prof Lutabingwa’s contributions extend beyond workshops. He will collaborate with Dr Grey Magaiza, Director of the Centre for Gender and Africa Studies, and other faculty members on co-authoring two research articles. This collaboration aims to strengthen the UFS' research profile and contribute to a more impactful research landscape.

Dr Magaiza highlights the significance of Prof Lutabingwa’s visit: "Jesse is at the heart of the UFS-AppState partnership. Now, as a Carnegie Africa Diaspora fellow, he can engage with us in a new way, pouring his expertise back into this space. His grant-writing workshops and collaborative research efforts will be instrumental in achieving our third-stream aspirations."

Excited about the future

The fellow’s enthusiasm for this fellowship is noticeable when he speaks and engages with colleagues on campus. "Words cannot express my excitement," he shares. "I am grateful for this opportunity to collaborate, engage in research, and connect with various individuals on campus."

The UFS community warmly welcomes Prof Lutabingwa and anticipates a fruitful fellowship that will empower faculty, strengthen research, and propel the UFS – particularly the Qwaqwa Campus – towards achieving its third-income aspirations.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept